Astria Therapeutics, Inc. (ATXS)
NASDAQ: ATXS · Real-Time Price · USD
5.33
-0.37 (-6.49%)
Mar 31, 2025, 1:43 PM EDT - Market open

Astria Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2015
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2015
Selling, General & Admin
35.2526.0319.7315.1512.36
Upgrade
Research & Development
76.3141.833.7815.2125.08
Upgrade
Operating Expenses
111.5667.8353.530.3637.44
Upgrade
Operating Income
-111.56-67.83-53.5-30.36-37.44
Upgrade
Interest & Investment Income
17.3610.21.720.120.24
Upgrade
Other Non Operating Income (Expenses)
-0.06-0.06-0.06-0.06-0.1
Upgrade
EBT Excluding Unusual Items
-94.26-57.69-51.83-30.3-37.3
Upgrade
Pretax Income
-94.26-72.89-51.83-194.91-37.3
Upgrade
Net Income
-94.26-72.89-51.83-194.91-37.3
Upgrade
Preferred Dividends & Other Adjustments
---24.44-
Upgrade
Net Income to Common
-94.26-72.89-51.83-219.35-37.3
Upgrade
Shares Outstanding (Basic)
56301593
Upgrade
Shares Outstanding (Diluted)
56301593
Upgrade
Shares Change (YoY)
86.44%106.03%63.81%191.81%63.87%
Upgrade
EPS (Basic)
-1.68-2.42-3.55-24.58-12.20
Upgrade
EPS (Diluted)
-1.68-2.42-3.55-24.58-12.20
Upgrade
Free Cash Flow
-81.54-68.47-43.62-30.17-32.52
Upgrade
Free Cash Flow Per Share
-1.45-2.27-2.98-3.38-10.63
Upgrade
EBITDA
-----37.41
Upgrade
D&A For EBITDA
----0.03
Upgrade
EBIT
-111.56-67.83-53.5-30.36-37.44
Upgrade
Updated Mar 11, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q